Page 24 - GTM-3-1

Global Translational Medicine Role of HTS in cancer therapeutics

doi: 10.18632/oncotarget.212 55. Rossari F, Minutolo F, Orciuolo E. Past, present, and future
of Bcr‑Abl inhibitors: From chemical development to
44. Blay V, Tolani B, Ho SP, Arkin MR. High‑throughput
screening: Today’s biochemical and cell‑based approaches. clinical efficacy. J Hematol Oncol. 2018;11(1):84.
Drug Discov Today. 2020;25(10):1807‑1821. doi: 10.1186/s13045‑018‑0624‑2
doi: 10.1016/j.drudis.2020.07.024 56. Dong B, Liang Z, Chen Z, et al. Cryptotanshinone suppresses
key onco-proliferative and drug-resistant pathways of
45. Glickman JF. Assay development for protein kinase enzymes.
In: Markossian S, Grossman A, Brimacombe K, et al, editors. chronic myeloid leukemia by targeting STAT5 and STAT3
Assay Guidance Manual. United States: Eli Lilly & Company phosphorylation. Sci China Life Sci. 2018;61(9):999‑1009.
and the National Center for Advancing Translational doi: 10.1007/s11427‑018‑9324‑y
Sciences; 2004.
57. Liu C, Nie D, Li J, et al. Antitumor effects of blocking
46. Harner MJ, Frank AO, Fesik SW. Fragment-based drug protein neddylation in T315I‑BCR‑ABL leukemia cells and
discovery using NMR spectroscopy. J Biomol NMR. leukemia stem cells. Cancer Res. 2018;78(6):1522‑1536.
2013;56(2):65‑75.
doi: 10.1158/0008‑5472.Can‑17‑1733
doi: 10.1007/s10858‑013‑9740‑z
58. Misra S, Zhang X, Wani NA, Sizemore S, Ray A. Both
47. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF BRCA1‑wild type and ‑mutant triple‑negative breast cancers
inhibitor needs broad target blockade in BRAF‑mutant show sensitivity to the NAE inhibitor MLN4924 which
melanoma. Nature. 2010;467(7315):596‑599. is enhanced upon MLN4924 and cisplatin combination
treatment. Oncotarget. 2020;11(8):784‑800.
doi: 10.1038/nature09454
doi: 10.18632/oncotarget.27485
48. Jadhav GP, Prathipati PK, Chauhan H. Surface plasmon
resonance, Orbitrap mass spectrometry and Raman 59. Swinney DC, Lee JA. Recent advances in phenotypic drug
advancements: Exciting new techniques in drug discovery. discovery. F1000Res. 2020;9:F1000.
Expert Opin Drug Discov. 2020;15(7):739‑743.
doi: 10.12688/f1000research.25813.1
doi: 10.1080/17460441.2020.1745771
60. McKinney JD, Richard A, Waller C, Newman MC,
49. Imaduwage KP, Lakbub J, Go EP, Desaire H. Rapid LC‑MS Gerberick F. The practice of structure activity relationships
based high-throughput screening method, affording no false (SAR) in toxicology. Toxicol Sci. 2000;56(1):8‑17.
positives or false negatives, identifies a new inhibitor for doi: 10.1093/toxsci/56.1.8
carbonic anhydrase. Sci Rep. 2017;7(1):10324.
61. Newman DJ, Cragg GM. Natural products as sources of new
doi: 10.1038/s41598‑017‑08602‑w
drugs over the nearly four decades from 01/1981 to 09/2019.
50. McLaren DG, Shah V, Wisniewski T, et al. High-throughput J Nat Prod. 2020;83(3):770‑803.
mass spectrometry for hit identification: Current landscape doi: 10.1021/acs.jnatprod.9b01285
and future perspectives. SLAS Discov. 2021;26(2):168‑191.
62. Krejci P, Pejchalova K, Wilcox WR. Simple, mammalian cell-
doi: 10.1177/2472555220980696
based assay for identification of inhibitors of the Erk MAP
51. Lu Y, Qin S, Zhang B, et al. Accelerating the throughput of kinase pathway. Invest New Drugs. 2007;25(4):391‑395.
affinity mass spectrometry-based ligand screening toward a G doi: 10.1007/s10637‑007‑9054‑7
protein-coupled receptor. Anal Chem. 2019;91(13):8162‑8169.
63. Chambers C, Smith F, Williams C, et al. Measuring
doi: 10.1021/acs.analchem.9b00477
intracellular calcium fluxes in high throughput mode. Comb
52. Gilbert IH. Drug discovery for neglected diseases: Molecular Chem High Throughput Screen. 2003;6(4):355‑362.
target-based and phenotypic approaches. J Med Chem. doi: 10.2174/138620703106298446
2013;56(20):7719‑7726.
64. Kariv I, Stevens ME, Behrens DL, Oldenburg KR. High
doi: 10.1021/jm400362b
throughput quantitation of cAMP production mediated
53. Chen GQ, Xu Y, Shen SM, Zhang J. Phenotype and by activation of seven transmembrane domain receptors.
target-based chemical biology investigations in cancers. Natl J Biomol Screen. 1999;4(1):27‑32.
Sci Rev. 2019;6(6):1111‑1127.
doi: 10.1177/108705719900400105
doi: 10.1093/nsr/nwy124
65. Eggert US, Kiger AA, Richter C, et al. Parallel chemical
54. Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted genetic and genome-wide RNAi screens identify cytokinesis
therapy in cancer. Chemother Res Pract. 2014;2014:357027. inhibitors and targets. PLoS Biol. 2004;2(12):e379.
doi: 10.1155/2014/357027 doi: 10.1371/journal.pbio.0020379

Volume 3 Issue 1 (2024) 16 https://doi.org/10.36922/gtm.2448